Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06303570 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
A Phase 2 study of Dercum's Disease, sponsored by Caliway Biopharmaceuticals Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06303570 is a Phase 2 study of Dercum's Disease that is actively recruiting participants, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06303570, a Phase 2 study of Dercum's Disease, is actively recruiting participants, sponsored by Caliway Biopharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
Conditions Studied
Interventions
- DRUG CBL-514 injection
- DRUG 0.9% Sodium chloride
Study Locations (1)
Washington
- Investigator Site - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06303570
The ClinicalTrials.gov registry entry for NCT06303570 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dercum's Disease appearing as the primary indexed condition, and to 2 interventions - of which CBL-514 injection is the first listed.
NCT06303570 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06303570 about?
NCT06303570 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas". This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
What is the current status of trial NCT06303570?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-11-27. Estimated completion is 2026-04.
What conditions does trial NCT06303570 study?
This clinical trial studies the following conditions: Dercum's Disease.
What interventions are being tested in trial NCT06303570?
The interventions under investigation include: CBL-514 injection (DRUG), 0.9% Sodium chloride (DRUG).
Who is sponsoring clinical trial NCT06303570?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06303570 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.